TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Deadly yet preventable: Cervical cancer screening, vaccination affected by COVID-19

Prior to the COVID-19 outbreak the medical community had pinned high hopes on efforts to tackle the prevalence of cervical cancer, which remains among the deadliest forms of the disease in the country despite it being the most preventable. However, the pandemic has disrupted mass screening and vaccination programs.

Ardila Syakriah (The Jakarta Post)
Premium
Jakarta
Sun, November 22, 2020

Share This Article

Change Size

Deadly yet preventable: Cervical cancer screening, vaccination affected by COVID-19 The high-risk HPV is a virus transmitted through sexual contact that is linked to 99 percent of cervical cancer cases, and with its vaccine, most of these cases are preventable. (Shutterstock/Chinnapong)

P

span id="docs-internal-guid-b186f169-7fff-ee8b-5ed6-f5c3a89ab124">Prior to the COVID-19 outbreak, the medical community had pinned high hopes on efforts to tackle the prevalence of cervical cancer, which remains among the deadliest types of malignant growth for women in Indonesia despite it being the most preventable. However, the pandemic has managed to disrupt mass screening and vaccination programs.

A four-year ongoing study of cervical cancer, carried out by Gadjah Mada University’s Center for Reproductive Health and the University of Melbourne’s Nossal Institute for Global Health, found that the number of patients seeking treatment in the capital Jakarta has declined.

The researchers started conducting interviews with dozens of workers from community-based organizations, clinics and hospitals in March, when the outbreak first erupted in the country, to find out why. They discovered that some medical services were adjusted as a result of the epidemic. As it turns out, there were fewer screenings for women, particularly pap smear and acetate acid (IVA) tests, which are used to diagnose cervical cancer. There were also fewer vaccines available for treating an infection of the human papillomavirus (HPV), which is the main cause of this type of cancer.

"If fewer women are going to be screened, then we won't be detecting cancer early, which means [...] women present for treatment [...] at the latest stages where it’s harder to save them," Nossal research fellow Belinda RM Spagnoletti, who focuses on sexual and reproductive health, told The Jakarta Post recently.

The high-risk HPV is a virus transmitted through sexual contact that is linked to 99 percent of cervical cancer cases, and with its vaccine, most of these cases are preventable.

Read also: Reasons not to skip your next smear test

The vaccination, however, is considered costly at around Rp 1 million (US$70.40), or a quarter of the Jakarta minimum wage, and is not part of the national immunization program.

to Read Full Story

We accept

TJP - Visa
TJP - Mastercard
TJP - GoPay
{

Your Opinion Counts

Your thoughts matter - share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.